摘要
目的观察奥沙利铂与替加氟持续静脉滴注联合化疗治疗晚期胃癌的临床疗效。方法21例均为不能手术的Ⅳ期胃癌病人。均接受奥沙利铂130mg/m2,静滴2h,第1天;替加氟600mg/m2,经微量泵持续24h静脉输入,第1～5天,3～4周为一周期,连用2周期后,4周评价疗效。结果21例患者中,CR0例,PR12例(57.1%),NC6例(28.6%),PD3例(14.3%),总有效率57.1%。中位缓解期4.6个月,中位生存期8.3个月,临床受益率85.7%。毒副反应主要是神经毒性、恶心、呕吐和腹泻等。结论奥沙利铂与替加氟持续静脉滴注联合化疗治疗晚期胃癌可获得较高疗效,毒副反应能耐受,可作为晚期胃癌的有效治疗方案,值得进一步研究。
Objective To evaluate clinical efficacy and toxicity of chemotherapy with Oxaliplatin（OXA） and Tegafur by continuous intravenous drip in treatment of advanced gastric cancer. Methods A total of 21 patients were pathologically confirmed as stage Ⅳ gastric cancer missing opportunity of surgical opera tion. OXA 130mg/m^2 was infused for two hours on dl, and Tegafur 600mg/m^2 was continuous infused by pump on dl to d5. One cycle comprised 3 ~4 weeks, and the efficacy was evaluated after 2 cycles and 4 weeks. Results In 21 patients,CR was seen in 0 patients and PR in 12 patients（57, l%）and NC in 6 patients（28. 6%）and PD in 3 patients（14. 3%） ,with total response rate of 57. 1%. The median remission period was 4. 6 months,the median survival period was 8. 3 months. The CBR was 85. 7%. The toxicity was mild neural toxicity and gastrointestinal tract toxicity. Conclusion OXA combined with Tegafur by pump for treatment of advanced gastric cancer has relatively high response rate, and the toxicity can bewell tolerated.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2007年第11期871-872,共2页
Cancer Research on Prevention and Treatment
关键词
奥沙利铂
替加氟
化疗
胃癌
OXA
Tegafur
Chemotherapy
Gastric cancer
